HOME Meetings and Progress on COS

HOME VIII (Seoul, South Korea)

Discussions will focus on identifing instrument(s) that are suitable for use in clinical practice for measuring itch and disease control.

HOME VII (Tokyo, Japan)

Discussions focused on reaching consensus for the Quality-of-life and Long-term control domains.

HOME VI (Utrecht, The Netherlands)

Discussions concerned identifying valid and feasible outcome measurement instruments for atopic eczema in routine clinical practice.

HOME V (Nantes, France)

Consensus was reached to recommend repeated measures of the signs, symptoms (including intensity of itch) and QoL for measuring long-term control in eczema trials. 

Instruments for measuring quality of life in children were assessed but no consensus was reached on recommending a core outcome instrument.

HOME IV (Malmö, Sweden)

Consensus was reached to recommend POEM as the core outcome instrument for measuring patient-reported symptoms in eczema trials. 

Instruments for measuring quality of life (QoL) in adults were assessed but no consensus was reached on recommending a core outcome instrument.

HOME III (San Diego, USA)

Consensus was reached to reccomend EASI as the core outcome instrument for measuring clinican reported signs of eczema trials.

HOME II (Amsterdam, the Netherlands)

Agreed the domains for the core outcome set as; clinician reported signs, patient reported symptoms, quality of life and long term control.

HOME I (Munich, Germany)

Determined there was sufficient interest to set up a HOME initiative to develop a COS.

An e-Delphi identified a preliminary core set of outcome domains for clinical trials and clinical record keeping.